Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Pfizer Inc.
EIR
•Pfizer Inc.•June 28, 2017

Pfizer Inc. – FDA EIR, Jun 28, 2017

Record Details

An FDA Bioresearch Monitoring inspection of Pfizer, Inc. was conducted from June 19 to June 28, 2017, at its Groton, CT facility. This pre-market inspection, requested by the FDA's Center for Drug Evaluation and Research, focused on Pfizer's sponsor responsibilities for the operational execution of two clinical study protocols associated with an investigational new drug application (IND 106,447) and a new drug application (NDA). The inspection adhered to compliance program CP 7348.810, which outlines guidelines for sponsors, contract research organizations, and monitors. During the review of various records, including monitoring plans, reports, and serious adverse event data, a significant observation was made. At the conclusion of the inspection, a Form FDA 483 was issued to Pfizer, citing a "Failure to ensure proper monitoring of the study." This finding indicates deficiencies in how the clinical trials were overseen. The FDA's Office of Bioresearch Monitoring East (OBIMO East) recommended a classification of Voluntary Action Indicated (VAI), meaning that although a deficiency was noted, official regulatory action is not anticipated, and the firm is expected to voluntarily correct the identified issue. The case was referred to CDER for final review and classification, emphasizing the need for Pfizer to address the monitoring shortcomings to ensure clinical study integrity.

Company
Pfizer Inc.
Inspection date
June 28, 2017
Product type
drugs
Office
New England District Office
People
  • Yolanda M. Patague (issuing_officer)
  • Kent A. Conforti (issuing_officer)
View Company Profile

ID · 52dfe47f-362a-44e3-adb8-479f50ec1e77

Violation Codes1
21 CFR 312

Full citation text and observation details available on the Dashboard.

Other documents for Pfizer Inc.
  • 483 - 2024-12-13December 13, 2024
  • EIR - 2021-01-08January 8, 2021
  • EIR - 2018-11-02November 2, 2018
  • EIR - 2018-07-18July 18, 2018
  • EIR - 2018-06-21June 21, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Pfizer Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.